Compare CIX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | STTK |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.5M | 275.9M |
| IPO Year | 1997 | 2020 |
| Metric | CIX | STTK |
|---|---|---|
| Price | $24.30 | $5.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.9K | ★ 574.2K |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | 17.04 | ★ 53.02 |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $158,285,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.38 | ★ N/A |
| Revenue Growth | ★ 8.46 | N/A |
| 52 Week Low | $17.89 | $0.69 |
| 52 Week High | $32.30 | $6.13 |
| Indicator | CIX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 72.78 |
| Support Level | $22.97 | $1.85 |
| Resistance Level | $24.90 | N/A |
| Average True Range (ATR) | 0.37 | 0.40 |
| MACD | -0.05 | 0.17 |
| Stochastic Oscillator | 43.13 | 89.34 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.